FDA Panel: Bristol Diabetes Drug Heart-Safe

Wed, 04/01/2009 - 11:26am
SILVER SPRING, Md. (AP) — Government experts say a potential blockbuster diabetes drug from Bristol-Myers Squibb does not carry heart problems seen with similar treatments in recent years. Bristol-Myers and partner AstraZeneca have asked the Food and Drug Administration to approve their drug Onglyza for millions of Americans with type 2 diabetes. The FDA panel voted 10 to 2 that the companies' data rule out the risk that the drug hastens heart attack, stroke and other problems. The drug is the first to go before the panel of diabetes experts since the agency issued new safety guidelines for diabetes treatments. The recommendation is reassuring to a slew of drugmakers working on treatments to compete in the $5 billion U.S. diabetes drug market.

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.